glutathione iv for parkinsons disease Therapy glutathione iv and parkinson s

View AOD-9604 Browse the full catalog Research Snapshot Head-to-head comparison Provider pricing, medication availability, pharmacy partners, insurance support, and cancellation rules can change quickly

Disclosures: Xiaoyang Yang: Nothing to Disclose, Dengqiang Chen: Nothing to Disclose, Zhaoqian Wang: Nothing to Disclose, Yuanyong Wang: Nothing to Disclose, Min Liao: Nothing to Disclose, Jiao Wang: Nothing to Disclose, Feng Lin: Nothing to Disclose, Biao Wu: Nothing to Disclose 544 VALIDATION OF AN ARTIFICIAL INTELLIGENCE MODEL FOR PREDICTION OF HEPATOCELLULAR CARCINOMA RISK AFTER ORAL ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C Yu Rim Lee 1 Hyun Young Woo 2 Young Oh Kweon 3 Won Young Tak 4 Se Young Jang 3 Jung Gil Park 5 Min Kyu Kang 5 Jeong Eun Song 6 Jeong Heo 2 Jeong Hwa Lee 7 Min Hwa Park 3 Hyunyeol Lee 8 Soo Young Park 3 , 1 Kyungpook National University, Kyungpook National University, 2 Pusan National University and Medical Research Institute, Pusan National University Hospital, 3 Kyungpook National University, Kyungpook National University Hospital, 4 College of Medicine, Kyungpook National University, 5 Yeungnam University College of Medicine, 6 Daegu Catholic University School of Medicine, 7 Kyungpook National University, Kyungpook National University Chilgok Hospital, 8 School of Electronics Engineering, Kyungpook National University Background: Hepatocellular carcinoma (HCC) can still occur after achieving a sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with hepatitis C

B 116 , 28422849 (2012)

Mau, J.L